Overview Phase I Trial of PX-478 Status: Completed Trial end date: 2010-05-01 Target enrollment: Participant gender: Summary This study is being conducted to determine the safety and biologic activity of PX-478, and to allow for observation of any preliminary evidence of antitumor activity in patients with advanced metastatic cancer. Phase: Phase 1 Details Lead Sponsor: Cascadian Therapeutics Inc.